GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Smruthi Organics Ltd (BOM:540686) » Definitions » Total Liabilities

Smruthi Organics (BOM:540686) Total Liabilities : ₹0 Mil (As of Jun. 2024)


View and export this data going back to 2005. Start your Free Trial

What is Smruthi Organics Total Liabilities?

Smruthi Organics's Total Liabilities for the quarter that ended in Jun. 2024 was ₹0 Mil.

Smruthi Organics's quarterly Total Liabilities increased from Dec. 2023 (₹0.00 Mil) to Mar. 2024 (₹485.72 Mil) but then declined from Mar. 2024 (₹485.72 Mil) to Jun. 2024 (₹0.00 Mil).

Smruthi Organics's annual Total Liabilities increased from Mar. 2022 (₹204.52 Mil) to Mar. 2023 (₹374.84 Mil) and increased from Mar. 2023 (₹374.84 Mil) to Mar. 2024 (₹485.72 Mil).


Smruthi Organics Total Liabilities Historical Data

The historical data trend for Smruthi Organics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Smruthi Organics Total Liabilities Chart

Smruthi Organics Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 452.87 313.29 204.52 374.84 485.72

Smruthi Organics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 354.89 - 485.72 -

Smruthi Organics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Smruthi Organics's Total Liabilities for the fiscal year that ended in Mar. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=420.615+(56.481+8.624
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=486

Total Liabilities=Total Assets (A: Mar. 2024 )-Total Equity (A: Mar. 2024 )
=1181.907-696.187
=486

Smruthi Organics's Total Liabilities for the quarter that ended in Jun. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=N/A

Total Liabilities=Total Assets (Q: Jun. 2024 )-Total Equity (Q: Jun. 2024 )
=N/A-N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Smruthi Organics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Smruthi Organics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Smruthi Organics Business Description

Traded in Other Exchanges
N/A
Address
165-A, Balaji Bhavan, 1st Floor, Railway Lines, Solapur, MH, IND, 413 001
Smruthi Organics Ltd is engaged in the manufacture of bulk drugs and drug intermediates (API Products). The product portfolio includes Amlodipine Besilate, Amlodipine Base, S-Amlodipine Besilate, S-Amlodipine Base, Norfloxacin, Metformin HCI, Diloxanide Furoate, Phthaloyl Amlodipine, Pantoprazole Sodium, Pefloxacin Mesylate Dihydrate, Telmisartan, Losartan Potassium and many more. It has two segments Bulk Drugs and Drugs Intermediates (API) and Formulation. it generates the majority of its revenue from the Bulk Drugs and Drugs Intermediates (API) segment.

Smruthi Organics Headlines

No Headlines